Sun Pharma Q3FY26 Preview: Growth Expected

Sun Pharma, a big Indian medicine company, is going to share its results for the third part of the year.

People who study the company think it will make a little more money than last year, but a bit less than the last three months.

This is because one of their important cancer drugs, Revlimid, is selling less.

But they have other new and special medicines that might make up for this, like Leqselvi for hair loss and others.

In India, they are expected to grow a lot, more than the whole Indian medicine market.

They might spend more on telling people about their new medicines, which could make their profits stay the same or go down a little.

People are also watching to see if new rules in the US about medicine prices will affect them.

Also, they just got permission to sell a weight-loss medicine in India once its patent ends.